Literature DB >> 27097828

The role of integrins in primary and secondary brain tumors.

Jens Schittenhelm1, Ghazaleh Tabatabai2, Bence Sipos3.   

Abstract

The tumor environment plays an integral part in the biology of cancer, participating in tumor initiation, progression, and response to therapy. Integrins, a family of cell surface receptors, bridge the extracellular matrix to the intracellular cytoskeleton. Since their first characterization 25 years ago, a vast amount of work has been performed to understand the essential role of integrins in cell development, tissue organization, tumor growth, vessel development and their signaling mechanisms. Their potential as therapeutic targets in various types of cancer is intensively studied. In this review, we discuss the expression patterns and functional role of integrin in primary brain tumors and brain metastases, provide an overview of clinical data on integrin inhibition and their potential application in imaging and therapy of these tumors.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27097828     DOI: 10.14670/HH-11-7741

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  3 in total

1.  [99mTc]-labeling and evaluation of a new linear peptide for imaging of glioblastoma as a αvβ3-positive tumor.

Authors:  Sajad Kaihani; Nourollah Sadeghzadeh; Saeid Abediankenari; Seyed Mohammad Abedi
Journal:  Ann Nucl Med       Date:  2022-09-12       Impact factor: 2.258

Review 2.  Integrins promote axonal regeneration after injury of the nervous system.

Authors:  Bart Nieuwenhuis; Barbara Haenzi; Melissa R Andrews; Joost Verhaagen; James W Fawcett
Journal:  Biol Rev Camb Philos Soc       Date:  2018-02-15

3.  Adhesion- and stress-related adaptation of glioma radiochemoresistance is circumvented by β1 integrin/JNK co-targeting.

Authors:  Anne Vehlow; Erik Klapproth; Katja Storch; Ellen Dickreuter; Michael Seifert; Antje Dietrich; Rebecca Bütof; Achim Temme; Nils Cordes
Journal:  Oncotarget       Date:  2017-07-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.